Biologic DMARDs (bDMARDs) confer a protective effect in patients with rheumatoid arthritis, lowering risk of developing sepsis as well as reducing mortality after serious infection and sepsis, according to results from a German registry presented at the 2015 ACR/ARHP Annual Meeting.
Adding methotrexate (MTX) to golimumab (GLM) therapy might significantly improve some symptoms among patients diagnosed with psoriatic arthritis (PsA), suggests a study reported at the 2015 ACR/ARHP Annual Meeting.
Long-term administration of mavrilimumab is safe and offers sustained clinical efficacy against moderate-to-severe rheumatoid arthritis (RA), according to an open-label extension study reported at the 2015 ACR/ARHP Annual Meeting
Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.
Longer-term efficacy and safety data from the Phase 3 PALACE 1 study have confirmed that apremilast continues to demonstrate sustained and clinically meaningful improvements in psoriatic arthritis signs and symptoms at 3 years in patients who remained on the treatment, investigators concluded at the 2015 ACR/ARHP Annual Meeting.
The safety and tolerability of pregabalin for the treatment of fibromyalgia-associated pain does not differ by baseline pain severity, a pooled analysis of five phase 3 clinical trials presented at the 2015 ACR/ARHP Annual Meeting has shown.
Phosphodiesterase 5 (PDE5) inhibitors appear to be effective in treating Raynaud’s phenomenon secondary to scleroderma, investigators concluded at the 2015 ACR/ARHP Annual Meeting.
Golimumab was well tolerated and effective in reducing symptom severity and improving disease outcomes in patients with ankylosing spondylitis over 12 months, a Canadian longitudinal study reported at the 2015 ACR/ARHP Annual Meeting.
Treatment with tabalumab did not significantly affect serum creatinine, glomerular filtration rate, or urine protein/creatinine ratio over 52 weeks vs. placebo, investigators reported at the 2015 ACR/ARHP Annual Meeting.
Data presented at the 2015 ACR/ARHP Annual Meeting showed that patients with active nonradiographic axial spondyloarthritis who received golimumab showed greater improvement in quality of life and work productivity outcomes than placebo.
